What Are the Treatment Options for Metastatic MPNST?

When Malignant Peripheral Nerve Sheath Tumor (MPNST) has spread to other parts of the body (metastasized), it is considered Stage IV or advanced disease. Hearing that your cancer is metastatic is incredibly difficult. Widespread metastatic MPNST is usually treated with the goal of controlling the disease, relieving symptoms, and maintaining your quality of life, rather than curing the cancer ^[1]. However, in carefully selected patients with very limited spread (often called oligometastatic disease), aggressive local treatments might occasionally offer prolonged disease control ^[2]. Because advanced MPNST is rare and challenging to treat, your care should be managed by a multidisciplinary team at a specialized sarcoma center ^[3].

Systemic Chemotherapy (First-Line Options)

Systemic therapies travel through the bloodstream to treat cancer cells throughout the body. Because there is no single regimen universally proven for MPNST, doctors typically adapt chemotherapy protocols used for other soft-tissue sarcomas ^[4]. The choice of treatment depends on your overall fitness, heart and kidney function, prior treatments, and personal goals.

• Doxorubicin: This is a common first-line chemotherapy for advanced MPNST ^[5]. It is often used on its own to help shrink tumors or slow their growth. Common side effects include low blood counts (increasing infection risk), nausea, mouth sores, hair loss, and cumulative heart damage over time ^[6].
• Ifosfamide: This drug is frequently combined with doxorubicin. While the combination may shrink tumors more effectively than doxorubicin alone, it does not necessarily result in longer overall survival ^[5]. Ifosfamide carries higher toxicity, including kidney or bladder injury and confusion (encephalopathy), requiring protective hydration and medications like mesna ^[6].

What to expect: A retrospective study of 115 patients with advanced MPNST found that first-line treatments kept the cancer from growing for a median of about 3.9 months, with a median overall survival of 15.0 months ^[5]. It is important to know that these are population averages; individual responses vary widely, and your experience could be substantially shorter or longer.

Safety Warning: If you are receiving chemotherapy, contact your care team immediately if you experience a fever, severe breathlessness, confusion, or an inability to keep fluids down.

What Happens if First-Line Treatment Stops Working?

Because advanced MPNST can be resistant to standard chemotherapy, the disease may eventually grow despite treatment ^[5]. If this happens, your team will discuss next steps. There is no universally effective second-line treatment for MPNST ^[7]. Options may include trying a different chemotherapy regimen, enrolling in a clinical trial, using targeted radiation for specific symptoms, or focusing entirely on supportive care based on your health and preferences.

Symptom-Directed Local Treatments

While systemic chemotherapy treats the whole body, specific tumors may cause intense pain, bleeding, or interfere with vital organs. Local treatments are highly individualized and depend on the number, size, and location of the tumors.

• Surgery: Surgery may be used to relieve pain, fix broken bones, or clear airway blockages ^[8]. For selected patients with only one or two isolated spots, a surgeon might attempt to remove them entirely (a procedure called metastasectomy) ^[2]. However, this is not appropriate for widespread disease.
• Radiation Therapy: Radiation can be highly effective at shrinking painful tumors or treating cancer that has spread to the bones ^[9][10].
• Brain Metastases: Spread to the brain is rare in MPNST. Treatment is determined by a specialist team and may involve surgery or stereotactic radiosurgery ^[11]. In highly selected cases at experienced centers, doctors may use Laser Interstitial Thermal Therapy (LITT)—a specialized, minimally invasive heat treatment—though it carries risks such as bleeding, swelling, and neurologic injury ^[12].

Emergency Warning: Severe or rapidly worsening back pain, new weakness or numbness in your limbs, or a sudden loss of bowel or bladder control could indicate spinal cord compression. This is a medical emergency requiring urgent evaluation and stabilization.

Supportive and Palliative Care

Palliative care focuses on improving your comfort and function; it does not mean you are giving up or that active treatment is stopping ^[10]. Palliative care specialists can work alongside your oncologist from the day of diagnosis to help manage pain, nerve symptoms, breathlessness, fatigue, and emotional distress. They also provide vital support with nutrition, rehabilitation, and advance care planning.

Investigational Therapies and Clinical Trials

Because standard chemotherapy offers limited long-term benefit, investigating clinical trials is a crucial part of your treatment plan ^[13]. It is highly recommended to ask about trials early in your journey, rather than waiting until standard options have been exhausted ^[3].

• Genomic Profiling: Your doctor may discuss testing your tumor’s DNA for specific mutations ^[14]. While this can occasionally identify a match for an experimental drug, many MPNSTs do not currently have targetable findings. If you have a history of Neurofibromatosis type 1 (NF1), genetic counseling is also recommended.
• MEK Inhibitors: While these drugs are established treatments for some benign NF1-related tumors (plexiform neurofibromas), they remain highly investigational for malignant MPNST ^[15]. Isolated case reports show responses in tumors with specific pathway mutations, but MEK inhibitors are not a standard care option for MPNST ^[15].
• Immunotherapy: Drugs that stimulate the immune system, like pembrolizumab, are currently being studied. While a few single-patient case reports show responses, immunotherapy does not reliably work for most MPNST patients and can cause serious immune-related side effects ^[16].
• Other Targeted Agents: Researchers are studying drugs that target other pathways, such as mTOR inhibitors and a drug called selinexor ^[17]. In one small 9-patient study, selinexor showed some ability to stabilize tumor growth, but like other targeted agents, it remains an early-stage, investigational approach ^[18].